This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Hypertension  • Randomized Controlled Trial  • Alert me on articles by topic

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group

JAMA. 2002;288:2981-2997.

Context  Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown.

Objective  To determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic.

Design  The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, active-controlled clinical trial conducted from February 1994 through March 2002.

Setting and Participants  A total of 33 357 participants aged 55 years or older with hypertension and at least 1 other CHD risk factor from 623 North American centers.

Interventions  Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years.

Main Outcome Measures  The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure [HF], and peripheral arterial disease).

Results  Mean follow-up was 4.9 years. The primary outcome occurred in 2956 participants, with no difference between treatments. Compared with chlorthalidone (6-year rate, 11.5%), the relative risks (RRs) were 0.98 (95% CI, 0.90-1.07) for amlodipine (6-year rate, 11.3%) and 0.99 (95% CI, 0.91-1.08) for lisinopril (6-year rate, 11.4%). Likewise, all-cause mortality did not differ between groups. Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, P = .03) and lisinopril (2 mm Hg, P<.001) groups compared with chlorthalidone, and 5-year diastolic blood pressure was significantly lower with amlodipine (0.8 mm Hg, P<.001). For amlodipine vs chlorthalidone, secondary outcomes were similar except for a higher 6-year rate of HF with amlodipine (10.2% vs 7.7%; RR, 1.38; 95% CI, 1.25-1.52). For lisinopril vs chlorthalidone, lisinopril had higher 6-year rates of combined CVD (33.3% vs 30.9%; RR, 1.10; 95% CI, 1.05-1.16); stroke (6.3% vs 5.6%; RR, 1.15; 95% CI, 1.02-1.30); and HF (8.7% vs 7.7%; RR, 1.19; 95% CI, 1.07-1.31).

Conclusion  Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy.

ALLHAT Authors/Officers and Coordinators: Curt D. Furberg, MD, PhD; Jackson T. Wright, Jr, MD, PhD; Barry R. Davis, MD, PhD; Jeffrey A. Cutler, MD, MPH; Michael Alderman, MD; Henry Black, MD; William Cushman, MD; Richard Grimm, MD, PhD; L. Julian Haywood, MD; Frans Leenen, MD; Suzanne Oparil, MD; Jeffrey Probstfield, MD; Paul Whelton, MD, MSc; Chuke Nwachuku, MA, MPH; David Gordon, MD, PhD; Michael Proschan, PhD; Paula Einhorn, MD, MS; Charles E. Ford, PhD; Linda B. Piller, MD, MPH; J. Kay Dunn, PhD; David Goff, MD, PhD; Sara Pressel, MS; Judy Bettencourt, MPH; Barbara deLeon, BA; Lara M. Simpson, MS; Joe Blanton, MS; Therese Geraci, MSN, RN, CS; Sandra M. Walsh, RN; Christine Nelson, RN, BSN; Mahboob Rahman, MD; Anne Juratovac, RN; Robert Pospisil, RN; Lillian Carroll, RN; Sheila Sullivan, BA; Jeanne Russo, BSN; Gail Barone, RN; Rudy Christian, MPH; Sharon Feldman, MPH; Tracy Lucente, MPH; David Calhoun, MD; Kim Jenkins, MPH; Peggy McDowell, RN; Janice Johnson, BS; Connie Kingry, RN, BSN; Juan Alzate, MD; Karen L. Margolis, MD; Leslie Ann Holland-Klemme, BA; Brenda Jaeger; Jeffrey Williamson, MD, MHS; Gail Louis, RN; Pamela Ragusa, RN, BSN; Angela Williard, RN, BSN; R. L. Sue Ferguson, RN; Joanna Tanner; John Eckfeldt, MD, PhD; Richard Crow, MD; John Pelosi, RPh, MS.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interpreting Results of Clinical Trials: A Conceptual Framework
Singh et al.
CJASN 2008;3:1246-1252.
FULL TEXT  

Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular protection
Ferrari
Eur Heart J Suppl 2008;10:G13-G20.
ABSTRACT | FULL TEXT  

Which patients would benefit the most from the perindopril-amlodipine combination?
Danchin
Eur Heart J Suppl 2008;10:G29-G35.
ABSTRACT | FULL TEXT  

Should we prescribe diuretics for patients with prediabetes and hypertension?
Arroll et al.
BMJ 2008;337:a679-a679.
FULL TEXT  

The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
Hilgers and Mann
Nephrol Dial Transplant 2008;0:gfn455v1-gfn455.
FULL TEXT  

Developing an automated speech-recognition telephone diabetes intervention
Goldman et al.
Int J Qual Health Care 2008;20:264-270.
ABSTRACT | FULL TEXT  

High Perfusion Pressure Accelerates Renal Injury in Salt-Sensitive Hypertension
Mori et al.
J. Am. Soc. Nephrol. 2008;19:1472-1482.
ABSTRACT | FULL TEXT  

Heart Failure With Preserved Ejection Fraction: Treat Now by Treating Comorbidities
Shah and Gheorghiade
JAMA 2008;300:431-433.
FULL TEXT  

Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt and Alvarez
Diabetes Spectr. 2008;21:177-189.
ABSTRACT | FULL TEXT  

Burden and Rates of Treatment and Control of Cardiovascular Disease Risk Factors in Obesity: The Framingham Heart Study
Molenaar et al.
Diabetes Care 2008;31:1367-1372.
ABSTRACT | FULL TEXT  

Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute
Carter et al.
Hypertension 2008;52:30-36.
FULL TEXT  

Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
Calhoun et al.
Circulation 2008;117:e510-e526.
ABSTRACT | FULL TEXT  

Dihydropiridine calcium-channel blockers and perioperative mortality in aortic aneurysm surgery
Kertai et al.
Br J Anaesth 2008;0:aen173v1-8.
ABSTRACT | FULL TEXT  

Review: The therapeutic role of RAS blockade in chronic heart failure
Werner and Bohm
Therapeutic Advances in Cardiovascular Disease 2008;2:167-177.
ABSTRACT  

Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
Calhoun et al.
Hypertension 2008;51:1403-1419.
ABSTRACT | FULL TEXT  

Prevalence and incidence of hypertension from 1995 to 2005: a population-based study
Tu et al.
CMAJ 2008;178:1429-1435.
ABSTRACT | FULL TEXT  

Thiazide-Type Diuretics and {beta}-Adrenergic Blockers as First-Line Drug Treatments for Hypertension
Cutler and Davis
Circulation 2008;117:2691-2705.
FULL TEXT  

Reducing blood pressure in people of different ages
Staessen et al.
BMJ 2008;336:1080-1081.
FULL TEXT  

Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors
Solski and Longyhore
Am J Health Syst Pharm 2008;65:935-940.
ABSTRACT | FULL TEXT  

Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant et al.
J Am Coll Cardiol 2008;51:1865-1871.
ABSTRACT | FULL TEXT  

The role of percutaneous revascularization for renal artery stenosis
Dubel and Murphy
Vasc Med 2008;13:141-156.
ABSTRACT  

Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication
Gupta et al.
Diabetes Care 2008;31:982-988.
ABSTRACT | FULL TEXT  

Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT | FULL TEXT  

Pulse Wave Velocity Is an Independent Predictor of the Longitudinal Increase in Systolic Blood Pressure and of Incident Hypertension in the Baltimore Longitudinal Study of Aging
Najjar et al.
J Am Coll Cardiol 2008;51:1377-1383.
ABSTRACT | FULL TEXT  

Review: {beta}-blockers for hypertension increase risk of new onset diabetes
Belknap
Evid. Based Med. 2008;13:50-50.
FULL TEXT  

Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study
Os et al.
Hypertension 2008;51:1103-1108.
ABSTRACT | FULL TEXT  

Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 Diabetes
Bakris and Berkwits
ANN INTERN MED 2008;148:400-401.
FULL TEXT  

Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals
Stroup and Geddes
Schizophr Bull 2008;34:266-274.
ABSTRACT | FULL TEXT  

Management of Cardiovascular Disease in Renal Transplant Recipients
Shirali and Bia
CJASN 2008;3:491-504.
ABSTRACT | FULL TEXT  

Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition
Zannad et al.
Eur Heart J 2008;29:413-421.
ABSTRACT | FULL TEXT  

Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Black et al.
Diabetes Care 2008;31:353-360.
ABSTRACT | FULL TEXT  

Predicting Stroke Risk in Hypertensive Patients With Coronary Artery Disease: A Report From the INVEST
Coca et al.
Stroke 2008;39:343-348.
ABSTRACT | FULL TEXT  

Should We Target the Sympathetic Nervous System in the Treatment of Obesity-Associated Hypertension?
Biaggioni
Hypertension 2008;51:168-171.
FULL TEXT  

Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic Syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Wright et al.
Arch Intern Med 2008;168:207-217.
ABSTRACT | FULL TEXT  

Pharmacogenetic Association of the NPPA T2238C Genetic Variant With Cardiovascular Disease Outcomes in Patients With Hypertension
Lynch et al.
JAMA 2008;299:296-307.
ABSTRACT | FULL TEXT  

Publication of Clinical Trials in JAMA: Information for Authors
Fontanarosa and DeAngelis
JAMA 2008;299:95-96.
FULL TEXT  

Management of Hypertension in Diabetic Patients With Chronic Kidney Disease
Steigerwalt
Diabetes Spectr. 2008;21:30-36.
ABSTRACT | FULL TEXT  

Women and coronary disease
Andreotti and Marchese
Heart 2008;94:108-116.
FULL TEXT  

Cardiovascular Safety and Toxicity Profile of New Molecularly Targeted Anticancer Agents
Saad et al.
Am Soc Clin Oncol Ed Book 2008;2008:428-434.
ABSTRACT | FULL TEXT  

Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects
He et al.
J Clin Pharmacol 2008;48:85-95.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT  

Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease
Hu et al.
Eur Heart J 2007;28:3059-3066.
ABSTRACT | FULL TEXT  

A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial
Preston et al.
J Clin Pharmacol 2007;47:1555-1569.
ABSTRACT | FULL TEXT  

Stroke and Its Prevention in Chronic Kidney Disease
Khella and Bleicher
CJASN 2007;2:1343-1351.
ABSTRACT | FULL TEXT  

Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study
Shepherd et al.
CJASN 2007;2:1131-1139.
ABSTRACT | FULL TEXT  

Blood Pressure Control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Margolis et al.
Hypertension 2007;50:854-861.
ABSTRACT | FULL TEXT  

In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study
Okin et al.
Hypertension 2007;50:984-990.
ABSTRACT | FULL TEXT  

Pharmacokinetics and Pharmacodynamics of Drospirenone-Estradiol Combination Hormone Therapy Product Coadministered With Hydrochlorothiazide in Hypertensive Postmenopausal Women
Karara et al.
J Clin Pharmacol 2007;47:1292-1302.
ABSTRACT | FULL TEXT  

Thiazide Diuretics Exacerbate Fructose-Induced Metabolic Syndrome
Reungjui et al.
J. Am. Soc. Nephrol. 2007;18:2724-2731.
ABSTRACT | FULL TEXT  

Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling
Ogino et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H2271-H2280.
ABSTRACT | FULL TEXT  

Tissue ACE Inhibitors for Secondary Prevention of Cardiovascular Disease in Patients With Preserved Left Ventricular Function: A Pooled Meta-analysis of Randomized Placebo-controlled Trials
Saha et al.
J CARDIOVASC PHARMACOL THER 2007;12:192-204.
ABSTRACT  

Race and Ethnicity in Trials of Antihypertensive Therapy to Prevent Cardiovascular Outcomes: A Systematic Review
Park and Taylor
Ann Fam Med 2007;5:444-452.
ABSTRACT | FULL TEXT  

Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials
Helman et al.
Chest 2007;132:764-772.
ABSTRACT | FULL TEXT  

Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases
Borer
Eur Heart J Suppl 2007;9:E2-E9.
ABSTRACT | FULL TEXT  

Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats
Gilliam-Davis et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H1327-H1333.
ABSTRACT | FULL TEXT  

Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Population
Aksnes et al.
Hypertension 2007;50:467-473.
ABSTRACT | FULL TEXT  

Is There an Unrecognized Epidemic of Primary Aldosteronism? (Pro)
Calhoun and Kaplan
Hypertension 2007;50:447-453.
FULL TEXT  

Isolated Systolic Hypertension in the Elderly
Chobanian
NEJM 2007;357:789-796.
FULL TEXT  

Compliance With Joint National Committee 7 Guidelines in Hypertension Management in a Teaching Institution
Jami et al.
American Journal of Medical Quality 2007;22:251-258.
ABSTRACT  

Which Targets in Clinical Practice Guidelines Are Associated with Improved Survival in a Large Dialysis Organization?
Tentori et al.
J. Am. Soc. Nephrol. 2007;18:2377-2384.
ABSTRACT | FULL TEXT  

REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention
Rosendorff et al.
Hypertension 2007;50:e28-e55.
FULL TEXT  

Hypertension, Proteinuria, and Antagonism of Vascular Endothelial Growth Factor Signaling: Clinical Toxicity, Therapeutic Target, or Novel Biomarker?
van Heeckeren et al.
JCO 2007;25:2993-2995.
FULL TEXT  

The Record on Rosiglitazone and the Risk of Myocardial Infarction
Psaty and Furberg
NEJM 2007;357:67-69.
FULL TEXT  

The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Nogueira and Weir
CJASN 2007;2:766-785.
ABSTRACT | FULL TEXT  

Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: A Quantitative Overview
Wang et al.
Hypertension 2007;50:181-188.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT  

Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model
Fujihara et al.
Am. J. Physiol. Renal Physiol. 2007;292:F1810-F1818.
ABSTRACT | FULL TEXT  

Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?: Time for Another Look
Reudelhuber et al.
Hypertension 2007;49:1196-1201.
FULL TEXT  

Similar Effects of Treatment on Central and Brachial Blood Pressures in Older Hypertensive Subjects in the Second Australian National Blood Pressure Trial
Dart et al.
Hypertension 2007;49:1242-1247.
ABSTRACT | FULL TEXT  

Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention
Rosendorff et al.
Circulation 2007;115:2761-2788.
FULL TEXT  

beta blockers in hypertension and cardiovascular disease
Ong
BMJ 2007;334:946-949.
FULL TEXT  

Nurse Care Manager Collaboration With Community-Based Physicians Providing Diabetes Care: A Randomized Controlled Trial
Hiss et al.
The Diabetes Educator 2007;33:493-502.
ABSTRACT | FULL TEXT  

Do Newer Prescription Drugs Pay For Themselves? A Reassessment Of The Evidence
Zhang and Soumerai
Health Aff (Millwood) 2007;26:880-886.
ABSTRACT | FULL TEXT  

World Hypertension Day 2007
Jones and Hall
Hypertension 2007;49:939-940.
FULL TEXT  

First-Line Therapy for Hypertension
Eledrisi
ANN INTERN MED 2007;146:615-615.
FULL TEXT  

A Candidate Hypertension Gene: Will SPON1 Hold Salt and Water?
Heximer and Husain
Circ. Res. 2007;100:940-942.
FULL TEXT  

Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease
Deepak et al.
Postgrad. Med. J. 2007;83:277-280.
ABSTRACT | FULL TEXT  

Do Statins Reduce Blood Pressure?: A Meta-Analysis of Randomized, Controlled Trials
Strazzullo et al.
Hypertension 2007;49:792-798.
ABSTRACT | FULL TEXT  

Treating to target in type 2 diabetes
Keigher et al.
British Journal of Diabetes & Vascular Disease 2007;7:83-85.
ABSTRACT  

Hypokalaemia and sudden cardiac death--lessons from implantable cardioverter defibrillators
Maeder et al.
Emerg. Med. J. 2007;24:206-208.
ABSTRACT | FULL TEXT  

Aliskiren for Renin Inhibition: A New Class of Antihypertensives
Van Tassell and Munger
The Annals of Pharmacotherapy 2007;41:456-464.
ABSTRACT | FULL TEXT  

Lercanidipine in the Treatment of Hypertension
Beckey et al.
The Annals of Pharmacotherapy 2007;41:465-473.
ABSTRACT | FULL TEXT  

Response to Target Blood Pressure Level Before Antihypertensive Class to Improve Outcomes More Quickly in Uncomplicated Hypertension
Ma et al.
Hypertension 2007;49:e17-e17.
FULL TEXT  

Diuretics were superior to calcium channel blockers and short term ACE inhibitors for reducing heart failure in hypertension
Rudd
Evid. Based Med. 2007;12:17-17.
FULL TEXT  

Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?
Robinson et al.
Stroke 2007;38:441-450.
ABSTRACT | FULL TEXT  

Clinical Trials for Hypertension: Expectations Fulfilled and Unfulfilled
Kaplan
Hypertension 2007;49:257-259.
FULL TEXT  

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association
Buse et al.
Circulation 2007;115:114-126.
ABSTRACT | FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT  

Treatment and control of blood pressure in patients with diabetes mellitus
Choe et al.
Am J Health Syst Pharm 2007;64:97-103.
ABSTRACT | FULL TEXT  

Persistence, Adherence, and Risk of Discontinuation Associated with Commonly Prescribed Antihypertensive Drug Monotherapies
Elliott et al.
J Am Board Fam Med 2007;20:72-80.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2007
American Diabetes Association
Diabetes Care 2007;30:S4-S41.
FULL TEXT